Dear Members and Friends of SwissCham,
Last week, the Life Sciences Committee of SwissCham organized a highly successful event titled “中国生命科学行业创新与未来发展论坛 / Swiss Healthcare Innovation in China: A Forward Overview on Business and Policies.”
The event provided attendees with valuable insights into the evolving policy trends in the Life Sciences landscape in China. It offered a comprehensive understanding of the Volume Based Procurement (VBP) regulatory framework and highlighted localization strategies and best practices necessary for companies to thrive and expand in the market. The seminar session was followed by an engaging discussion forum, which proved to be highly effective in facilitating the exchange of information and strengthening the network of Swiss companies in the Life Sciences business community. This platform not only provided valuable knowledge but also fostered valuable connections among participants, enhancing collaboration and potential business opportunities.
We would also like to extend our sincere thanks to David Vanni, Senior Brand Manager at Novartis, Vice President of SwissCham Shanghai, and Chairman of the Life Science Committee; Roger Germann, Head of Business Development and External Affairs at Geistlich, Board Director of SwissCham Beijing, and Vice Chairman of the Life Sciences Committee; and Enrico Magnani, Group Chief Strategy Officer at Helsinn Pharmaceuticals China, and Vice Chairman of the Life Sciences Committee.
Furthermore, we would like to extend our gratitude to Martin Matter, Head of Economic and Financial Section at the Embassy of Switzerland in China; Bin Jiang 江滨, Deputy Director of the Center for Public Policy Research at Peking University and Vice Chairman of the Professional Committee on Pharmacy Management of the Beijing Pharmaceutical Society; Fan Zhang 张凡, Deputy Director of the Investment Promotion Bureau of the Ministry of Commerce; Libo Tao 陶立波, Researcher at the Center for Health Policy and Technology Evaluation, Department of Medicine, Peking University; Yu Peng 彭宇, Senior Corporate Affairs Lead at Roche Diagnostics (Shanghai) Ltd.; Simon Liao 廖宁, Geistlich China CEO; Vicky Bai 白巍, Ypsomed China Project and Account Manager; Xiaojing Chen 陈小晶, Novartis Group (China) Senior Vice President; and Kaijun Jiang 姜凯军, Head of Corporate Affairs at Roche Pharmaceuticals China, for sharing their invaluable insights on volume-based procurement (VBP) and localization.
Your presence and contribution have greatly enriched the event, and the SwissCham Life Sciences Committee hopes that it has provided our member companies with valuable knowledge about market development and important policies in China’s life sciences industry.
We eagerly anticipate the opportunity to meet you again at our upcoming events in the near future.
